Sign in
Taking people in United StatesNo phase

Tests bright light therapy for Crohn's disease gut lining health

Tests bright light therapy against a placebo device in adults with Crohn's disease.

Key facts

Who runs it
Rush University Medical Center
Where
Charleston and Chicago, United StatesSee the 2 sites
Trial code
Registry title
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
Status
Recruiting
People taking part
30 people, planned
Started
22 Sept 2022
Expected to end
20 Feb 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Bright Light Therapy
  • Placebo Retimer Device
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Crohn's disease or ulcerative colitis, confirmed by biopsy, who are not in an active flare. Morning bright light therapy is tested against a placebo device.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Biopsy-proven Crohn's disease or ulcerative colitis. The disease must not be active (Harvey Bradshaw Index or Modified Harvey Bradshaw Index of 5 or less).
Earlier treatment
A stable dose of a biologic, an immunomodulator or 5-ASA for at least 12 weeks.
Biomarker or test result
Fecal Calprotectin > 50, or CRP above the upper limit of normal, or a PROMISE Fatigue score of 50 or more.

Main reasons for not taking part

  • Active IBD (Harvey Bradshaw Index > 5)
  • Major depression or suicidal intent on the Beck Depression scale
  • Sleep apnea or restless leg syndrome
  • Regular use of medicines that affect gut permeability or melatonin in the 4 weeks before the study
  • Night shift work or crossing more than 2 time zones in the past month

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Biopsy proven diagnosis of Crohn's or Ulcerative Colitis
  • 18 years or older
  • Fecal Calprotectin > 50 or CRP above upper limit of normal or a PROMISE Fatigue ≥ 50
  • Has been on a stable dose of either a biologic, immunomodulator, or 5-ASA for at least 12 weeks

Who cannot take part

  • Regular use of medications that affect intestinal permeability, and/or endogenous melatonin including metoclopramide, NSAIDs, beta blockers, psychotropic medications, hypnotics and exogenous melatonin products during 4 weeks prior to the study
  • People who have worked night shifts or crossed more than 2 time zones in the previous month
  • Restless leg syndrome (score ≥ 15 on the IRLS Study Group Rating Scale(44))
  • Diagnosis of narrow angle glaucoma or retinal disorders or demonstrated symptoms indicative of these diagnosis during the eligibility screening
  • Any major organ disease - renal impairment (creatinine>1.2 mg/dL), diabetes (Hgb-A1c > 6.5%); liver disease (LFTs > 1.5x normal), or significant cardiac failure (NY classification stage III/IV)
  • Active IBD (Harvey Bradshaw Index > 5 or Modified Harvey Bradshaw Index >5)
  • Major depression (score ≥ 21 or any endorsement of suicidal intent on the Beck Depression)
  • Sleep apnea (score high risk in 2 or more categories of the Berlin Questionnaire) (43)
  • Inability to sign an informed consent

Where in United States

  • Medical University of South CarolinaCharleston, United StatesContact: Katy DonovanTaking people
  • Rush University Medical CenterChicago, United StatesContact: Daynia Sanchez-BassTaking people

About the trial

What the trial wants to find out

Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the most significant chronic conditions of the gastrointestinal tract (GIT) and affects over 1.5 million individuals in the U.S. Recently, there has been an increased understanding of the importance of sleep and sleep disruption in IBD as a potentially modifiable risk factor. We, therefore, hypothesize that intervening with morning bright light therapy (BLT) in IBD patients with CM will decrease intestinal permeability and pro-inflammatory cytokines, positively impact intestinal microbiota, and improve quality of life (QoL).

The 2 groups in the trial

  • Bright Light Therapy via ReTimer glasses, Then PlaceboTreatment being tested

    Participants will wear their device for 60 minutes every morning for 28-days (4 weeks)

    Treatment: Bright Light Therapy and Placebo Retimer Device

  • No Bright Light Therapy via placebo glasses, Then Bright Light TherapyTreatment being tested

    Participants will wear their placebo device for 60 minutes every morning for 28-days (4 weeks)

    Treatment: Bright Light Therapy and Placebo Retimer Device

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
Plain-language title
Tests bright light therapy for Crohn's disease gut lining healthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 October 2026